Sputnik-V vaccine is 92% effective: Lancet
The phase 3 trial results of the Russian offering have been published in the prestigious peer-review journal
The Russian-developed Sputnik V vaccine has been found to be 91.6% effective against COVID-19, according to a study published in The Lancet.
The peer-reviewed result comes from a phase 3 clinical trial conducted in the Russian capital Moscow by the Gamaleya National Centre of Epidemiology and Microbiology, the body that developed the vaccine.
